Well-being in the families of people with schizophrenia

Haematological monitoring with clozapine therapy in lndia Chromosome 22ql I delet~ons and aggressive behaviour Well-being in the families of people with schizophrenia 5-HT2 neurotransmission in major depression Active placebos in antidepressant trials Haematological monitoring with clozapine therapy in lndiaSir: Clozapine was introduced in lndia in 1995 and some brands of the drug are now available for the equivalent of around £0.25 for 300 mg clozapine.Unfortunately, affordability is still a problem for many people with schizophrenia, as added to drug costs are the costs of weekly haematological monitoring (£0.25-0.75)and travel.The frequency and duration of haematological monitoring are factors that influence the cost and acceptability of therapy.Studies from the USA (Alvir et al, 1993) and the UK (Atkin et al, 1996) reported a drastic fall in the incidence of agranulocytosis or neutropenia after the first 12 months of clozapine treatment.Long-term